Developing novel lentiviral vectors into clinical products

Anna Leath, Kenneth Cornetta

Research output: Contribution to journalArticle

12 Scopus citations


Gene therapy vectors based on murine retroviruses have now been in clinical trials for over 20 years. During that time, a variety of novel vector pseudotypes were developed in an effort to improve gene transfer. Lentiviral vectors are now in clinical trials and a similar evolution of vector technology is anticipated. These modifications present challenges for those producing large-scale clinical materials. This chapter discusses approaches to process development for novel lentiviral vectors, highlight considerations, and methods to be incorporated into the development schema.

Original languageEnglish
Pages (from-to)89-108
Number of pages20
JournalMethods in Enzymology
StatePublished - 2012


  • Clinical vector production
  • Gene therapy vectors
  • Lentiviral vectors
  • Replication competent lentivirus
  • Vector certification
  • Vector pseudotypes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'Developing novel lentiviral vectors into clinical products'. Together they form a unique fingerprint.

  • Cite this